Mr Joyce succeeds Mark Durand, who has departed as CFO for personal reasons. On July 27, 2009, Watson announced that Mr Durand had taken a leave of absence for health reasons, and named Mr Joyce as acting principal financial officer.
Mr Joyce joined Watson in 1997 as corporate controller, and was named vice president, corporate controller and treasurer in 2001. During the period of October 2006 to November 2007, Mr Joyce served as interim principal financial officer.
Paul Bisaro, president and CEO of Watson Pharmaceuticals, said: "We are fortunate that Todd, who has served in a variety of senior financial positions within the company over the past 12 years, has agreed to become our new CFO. Todd's financial expertise and his history within the organization will enable him to perform these duties, and to continue the good work begun by Mark during his tenure."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index